Details for Patent: 8,652,527

Which drugs does patent 8,652,527 protect, and when does it expire?

Patent 8,652,527 protects QUDEXY XR and is included in one NDA.

This patent has ten patent family members in six countries.

Summary for Patent: 8,652,527

Title:	Extended-release topiramate capsules
Abstract:	An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s).
Inventor(s):	Betterman; Sarah Michelle (Champlin, MN), Tantry; Jaidev Srinvas (Maple Grove, MN), Patrick; Laura Marie (Eden Prairie, MN)
Assignee:	Upsher-Smith Laboratories, Inc (Maple Grove, MN)
Application Number:	13/847,042
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,652,527
Patent Claim Types: see list of patent claims	Composition; Dosage form;

Drugs Protected by US Patent 8,652,527

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Upsher Smith Labs	QUDEXY XR	topiramate	CAPSULE, EXTENDED RELEASE;ORAL	205122-001	Mar 11, 2014	AB2	RX	Yes	No			Y
Upsher Smith Labs	QUDEXY XR	topiramate	CAPSULE, EXTENDED RELEASE;ORAL	205122-002	Mar 11, 2014	AB2	RX	Yes	No			Y
Upsher Smith Labs	QUDEXY XR	topiramate	CAPSULE, EXTENDED RELEASE;ORAL	205122-003	Mar 11, 2014	AB2	RX	Yes	No			Y

International Family Members for US Patent 8,652,527

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Brazil	112015022434
Canada	2905011
European Patent Office	2968177